H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) on Wednesday, setting a price target of $175, which is approximately 56.35% above the present share price of $111.93.
Livnat expects Jazz Pharmaceuticals to post earnings per share (EPS) of -$2.82 for the third quarter of 2020.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Jazz Pharmaceuticals, with an average price target of $163.9.
The analysts price targets range from a high of $195 to a low of $113.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $534.73 million and a net profit of $148.72 million. The company's market cap is $6.11 billion.
According to TipRanks.com, H.C. Wainwright analyst Oren Livnat is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 2.7% and a 46.82% success rate.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.